본문 바로가기

Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1
저널
AMERICAN JOURNAL OF CARDIOLOGY105(6) · pp.813 · 2010
피인용
Web of Science 16
JCR IF
JCR 2009 3.575
ISSN
0002-9149

저자

  1. Kim, Hyun Kuk제1저자전남대학교, KO
  2. Jeong, Myung Ho전남대학교, KO
  3. Ahn, Young Keun전남대학교, KO
  4. Kim, Jong Hyun수영한서병원, KO
  5. Chae, Shung Chull경북대학교, KO
  6. Kim, Young Jo영남대학교, KO
  7. Hur, Seung Ho계명대학교, KO
  8. Seong, In Whan충남대학교, KO
  9. 홍택종부산대학교, 의과대학, 의학과, 내과학교실, KO
  10. Choi, Dong Hoon연세대학교, Severans Hosp, KO
  11. Cho, Myeong Chan충북대학교, KO
  12. Kim, Chong Jin경희대학교, KO
  13. Seung, Ki Bae가톨릭대학교, KO
  14. Chung, Wook Sung가톨릭대학교, KO
  15. Jang, Yang Soo연세대학교, KO
  16. Rha, Seung Woon고려대학교, KO
  17. Bae, Jang Ho건양대학교, KO
  18. Cho, Jeong Gwan전남대학교, KO
  19. Park, Seung Jung울산대학교, KO

초록

Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% Cl 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:813-818)

키워드

CORONARY-ARTERY-DISEASEHEART-FAILUREENDEAVOR-IITRIAL

식별자

WoS UID
000278137300009